Gastrointestinal “mask” of heart failure: from symptoms to laboratory diagnostics

Given the high prevalence of cardiovascular pathologies, heart failure, as their common outcome, becomes a priority target for therapy and fundamental research. In recent years, increasing attention has been paid to the role of the microbiome in the pathogenesis of cardiovascular events. Under normal conditions, the gut flora and its metabolites are involved in maintaining the body’s homeostasis and represent an important component of immunological defense. In contrast, an imbalance of microorganisms leads to systemic inflammation and metabolic disorders. Gut dysbiosis is found in 90% of patients with cardiovascular diseases and is characterized by reduced microbiome diversity, an increase in pathogenic bacteria, and a decrease in the number of Lactobacillus and Bifidobacterium [8]. These changes can lead to increased levels of toxic metabolites, such as lipopolysaccharides and TMAO, resulting in inflammation, impaired cardiac function, and the realization of an atherogenic effect. The aim of the study was to assess the correlation between the severity of gastrointestinal symptoms and the degree of chronic heart failure (CHF) in cardiology patients. The study involved 159 patients from the cardiology department. The diagnosis of CHF was confirmed clinically, through laboratory tests, and instrumentally. The standard Gastrointestinal Symptom Rating Scale (GSRS) questionnaire was used to assess the severity of gastrointestinal complaints. The result is to reveal “cardiointestinal syndrome” as a new independent term. The study revealed a direct correlation between the severity of gastrointestinal symptoms and the NYHA functional class of CHF, but there were no correlation between EF and functional class of HF.

microbiota, microbiome, chronic heart failure, Gastrointestinal Symptom Rating Scale, cardio-intestinal syndrome, ejection fraction, EF, functional class

1. Lawson C.A., Zaccardi F., Squire I. et al. Risk Factors for Heart Failure. 20-Year Population-Based Trends by Sex, Socioeconomic Status, and Ethnicity. Circ HeartFail.2020;13(2): e006472. doi: 10.1161/CIRCHEARTFAILURE.119.006472: e006472.

2. Cohn J.N, Johnson G, Ziesche S., et al. A comparison of enalapril with Hydralazine-isosorbide dinitrate in thetreatment of chronic congestive heart failureN. EnglJ Med 1991;325:302-10.

3. Poole-Wilson P.A. Heart Failure: unfinished business - a possible role for vasodilators Int. J Cardiol.1993;40:1-6.

4. Poole-Wilson, Robinson K. Digoxin - a rebundant drug in the treatment of congestive heart failure. Cardiovasc Drugs Ther1989;2:733-41.

5. Ivanov D.O, Egay U.V. Vavilova T.V. et al. Cardiovascular diseases: the role of intestinal permeability and microbiota. University Therapeutic Bulletin. 2025; 7(2). (in Russ.) doi: 10.56871/UTJ.2025.43.18.001.@@ Иванов Д.О, Егай Ю.В. Вавилова Т.В. и соавт. Сердечно-сосудистые заболевания: роль кишечной проницаемости и микробиоты. Университетский терапевтический вестник. Том 7 № 2. 2025. DOI: 10.56871/UTJ.2025.43.18.001

6. Dostanko N.Yu., Yagur V.E., Zybalova T.S. The contribution of microbiota to the development, progression and outcomes of cardiovascular diseases. Literature review. Cardiology in Belaruss. (in Russ.) doi: 10.34883/PI.2022.14.5.010.@@ Достанко Н.Ю., Ягур В.Е., Зыбалова Т.С. Вклад микробиоты в развитие, прогрессирование и исходы сердечно-сосудистых заболеваний. Обзор литературы //doi.org/10.- Т. 34883.

7. Kostyukevich O.I. The influence of intestinal microflora on human health. From pathogenesis to modern methods of dysbiosis correction. Breast cancer. 2011;19(5):304-308.@@ Костюкевич О.И. Влияние кишечной микрофлоры на здоровье человека. От патогенеза к современным методам коррекции дисбиоза // РМЖ. - 2011. - Т. 19. - №. 5. - С. 304-308.

8. Tkacheva O.N., Kafarskaya L.I. The relationship of risk factors for cardiovascular diseases and the state of the vascular wall with the composition of the intestinal microbiota. (in Russ.) (Avaible at: https://gnicpm.ru/wp-content/uploads/2020/01/kashtanova_dissertation.pdf Accessed: 01.06.2025)@@ Ткачева О.Н., Кафарская Л.И. Взаимосвязь факторов риска сердечно-сосудистых заболеваний и состояния сосудистой стенки с составом микробиоты кишечника. URL: https://gnicpm.ru/wp-content/uploads/2020/01/kashtanova_dissertation.pdf

9. Vlasov A.A., Salikova S.P., Golovkin N.V., Grinevich V.B.Intestinal Microbial-tissue Complex and Chronic Heart Failure (part 1): Pathogenesis. Rational Pharmacotherapy in Cardiology. 2021;17(3):462-469. (In Russ.) doi: 10.20996/1819-6446-2021-06-12. @@ Власов А.А. и др. Микробно-тканевой комплекс кишечника и хроническая сердечная недостаточность (часть 1): патогенез. Рациональная фармакотерапия в кардиологии. 2021;17(3):462-469. doi: 10.20996/1819-6446-2021-06-12.

10. Dostanko N.Y., Yagur V.E., Zybalova T.S. Cardiology in Belarus Cardiology. 2022;14(5):642-652. (in Russ.)@@ Достанко н. Ю., Ягур В.Е., Зыбалова Т.С. Кардиология в Беларуси // кардиология. - 2022. - Т. 14. - №. 5. - С. 642-652.

11. Tutelyan V.A., Nikityuk D.B. [Key challenges in the dietary intake structure and cutting edge technologies for optimizing nutrition to protect the health of the Russian рopulation]. Vopr Pitan. 2024;93(1):6-21.Russian. doi: 10.33029/0042-8833-2024-93-1-6-21.@@ Тутельян В.А., Никитюк Д.Б. Ключевые проблемы в структуре потребления пищевой продукции и прорывные технологии оптимизации питания для здоровьесбережения населения России // Вопросы питания. - 2024. - Т. 93. - №. 1 (551). - С. 6-21.

12. Budnevsky A.V., Kravchenko A.Ya., Tokmachev R.E., Chernik T.A., Tokmachev E.V., Letnikova Yu.B. Diagnostic, prognostic and therapeutic possibilities of using the 6-minute walk test in patients with chronic heart failure. Cardiovascular therapy and prevention. 2020;19(6):2460. doi:10.15829/1728-8800-2020-2460.@@ Будневский А.В., Кравченко А.Я., Токмачев Р.Е., Черник Т.А., Токмачев Е.В., Летникова Ю.Б. Диагностические, прогностические и терапевтические возможности использования теста 6-минутной ходьбы у пациентов с хронической сердечной недостаточностью. Кардиоваскулярная терапия и профилактика. 2020;19(6):2460. doi:10.15829/1728-8800-2020-2460

13. Petrenko V.V. Clinical and pathogenetic features and ways of correcting intestinal dysbiosis and dyslipidemia in patients with functional constipation. Abstract of the dissertation … Candidate of Medical Sciences. St. Petersburg, 2009; 23 p. (in Russ.)@@ Петренко В.В. Клинико-патогенетические особенности и пути коррекциидисбиоза кишечника и дислипидемии у больных с функциональным запором.Автореф. дис. … канд. мед. наук. СПб, 2009; 23 с.

14. “Clinical guidelines for the treatment of CHF 2024” edited by Shlyakhto E.V., Tereshchenko S.N., Chesnokova A.I., Kobalava J.D.Russian Society of Cardiology. (in Russ.)@@ «Клинические рекомендации по лечению ХСН 2024 г.» под редакцией Шляхто Е.В., Терещенко С.Н., Чеснокова А.И., Кобалава Ж.Д. Российское кардиологическое общество.

15. Simadibrata DM, Auliani S, Widyastuti PA, Wijaya AD, Amin HZ, Muliawan HS, Siswanto BB, Simadibrata M. The Gut Microbiota Profile in Heart Failure Patients: A Systematic Review. J Gastrointestin Liver Dis. 2023 Sep 29;32(3):393-401. doi: 10.15403/jgld-4779. PMID: 3777421.

16. Fadeeva M.V., Skhirtladze M.R., Zolnikova O. Yu., Ivashkin V.T. “Gut microbiota in the pathogenesis of chronic heart failure”. Molecular Medicine,. 2022;20(2):11-18.@@ Фадеева М.В., Схиртладзе М.Р., Зольникова О.Ю., Ивашкин В.Т. «Микробиота кишечника в патогенезе хронической сердечной недостаточности» Молекулярная медицина, vol. 20, no. 2, 2022, pp. 11-18.

17. Egorova E.N., Kuzmina M.I., Mazur V.V., and others. Microbiocenosis and activity of the inflammatory process of the colon in patients with chronic heart failure. Clinical Medicine. 2012;90(7):46-8. EDN: RBINJL.@@ Егорова Е.Н., Кузьмина М.И., Мазур В.В., и др. Микробиоценоз и активность воспалительного процесса толстой кишки у больных хронической сердечной недостаточностью. Клиническая Медицина. 2012;90(7):46-8. EDN: RBINJL